Monitor pipeline development timelines for QTORIN rapamycin and pitavastatin; assess future cash burn and potential for additional dilution. The capital raise extends runway but does not alter near-term clinical risk profile.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 2 $132.61entry
- T+1 · 9mo ago −0.83%α +0.09% · $131.51
- T+5 · 8mo ago +3.08%α +4.29% · $136.70
- T+20 · 8mo ago −16.55%α −8.61% · $110.66
- T+60 · 6mo ago −11.33%α −20.65% · $117.59
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Palvella Therapeutics completed an upsized public offering of 1,840,000 shares at $125.00 per share, generating $230 million in gross proceeds. The capital will fund development of its QTORIN pipeline, including rapamycin and pitavastatin programs, and support general corporate purposes.
Key Financial Metrics
Key Facts
- Palvella closed a public offering of 1,840,000 shares of common stock at $125.00 per share.
- The offering included full exercise of the underwriters' option to purchase 240,000 additional shares.
- Gross proceeds totaled $230 million before underwriting discounts and expenses.
- Proceeds will be used to advance QTORIN rapamycin and QTORIN pitavastatin programs, and for working capital and R&D.
- The offering was conducted under a shelf registration (Form S-3) declared effective January 29, 2026.
Financial Impact
$230 million in gross proceeds; dilution estimated at approximately 10-12% based on $1.6B market cap
Risk Factors
- Dilution to existing shareholders from issuance of new shares
- No assurance of clinical success for QTORIN pipeline candidates
- Forward-looking statements about use of proceeds subject to execution risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3247266 |
Track record
36 reports on PVLA
4 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +35.07% at T+60 after the May 15, 2026 report. 8 of 10 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $145.21 Now $144.60 −0.42% settles Dec 16
- Nov 10, 20266d ago 144 Neutral 5/10 Entry $163.94 Now $144.60 −11.80% settles Dec 10
- Nov 5, 202611d ago 8-K Bullish 7/10 Entry $156.85 Now $144.60 −7.81% settles Dec 4
- Nov 5, 202611d ago Press Release Neutral 6/10 No price data
- Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $152.93 Now $144.60 −5.45% settles Dec 2
- Oct 28, 202619d ago SC 13G/A Neutral 3/10 Entry $147.47 Now $144.60 −1.95% settles Nov 25
- Oct 28, 202619d ago 8-K Bullish 6/10 Entry $147.47 Now $144.60 −1.95% settles Nov 25
- Oct 28, 202619d ago Press Release Bullish 7/10 Entry $147.47 Now $144.60 −1.95% settles Nov 25
- Oct 23, 202624d ago Insider Cluster Neutral 2/10 Entry $126.23 Now $144.60 +14.55% settles Nov 23
- Oct 15, 20264w ago Press Release Neutral 4/10 Entry $127.34 to $153.18 Now $144.60 +13.55% ▲ +20.29% +22.19% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers